Carbamazepine is not a substrate for P‐glycoprotein
Open Access
- 1 April 2001
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 51 (4), 345-349
- https://doi.org/10.1046/j.1365-2125.2001.01359.x
Abstract
Aims To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). Methods The role of Pgp in...Keywords
This publication has 18 references indexed in Scilit:
- Early Identification of Refractory EpilepsyNew England Journal of Medicine, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind studyThe Lancet, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cellsLeukemia Research, 1996
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- P-glycoprotein—A mediator of multidrug resistance in tumour cellsEuropean Journal Of Cancer, 1996
- New Advances in Vaccine Technologies and Applications: 13–15 February 1995, Bethesda, Maryland, USAVaccine, 1995
- MDR1 Gene Expression in Brain of Patients with Medically Intractable EpilepsyEpilepsia, 1995
- Epidemiology, classification, natural history, and genetics of epilepsyThe Lancet, 1990